SLC5A2 and diabetes mellitus: Moreover, patients with type 1 diabetes mellitus, β-cell failure in DM2, or who use sodium/glucose cotransporter 2 (SGLT2) inhibitors are also considered nonviable candidates for VLCKD due to the risk for euglycemic diabetic ketoacidosis in these populations [10].